Top

Published in:

01-10-2013 | Review Article

PET/CT in malignant lymphoma: basic information, clinical application, and proposal

Author: Ukihide Tateishi

Published in: International Journal of Hematology | Issue 4/2013

Abstract

Coregistered fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) provides functional and morphologic data useful for the management of lymphoma. PET/CT is a promising tool in initial staging/re-staging, monitoring post-treatment recurrence/exacerbation, and evaluating prognosis at mid-treatment use [interim PET/CT (iPET/CT)]. Many multicenter studies are currently underway to investigate the effectiveness and safety of stratified treatment protocols using iPET/CT. Thus, the establishment of a system focusing on standardization of image quality through established protocols for scanning or quality control (QC) of the acquired data and organization of a core laboratory facility to promote standardization would be beneficial. Uniformity of image quality across multiple institutions can be guaranteed through optimization of imaging conditions and appropriate QC of PET/CT scanners to ensure standardization. Further research is required to ensure the standardization of PET/CT protocols used in the management of malignant lymphoma.

Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110:3507–16.PubMedCrossRef

Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian–Danish study. J Clin Oncol. 2007;25:3746–52.PubMedCrossRef

Schot BW, Pruim J, van Imhoff GW, Sluiter WJ, Vaalburg W, Vellenga E. The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. Haematologica. 2006;91:490–5.PubMed

Roland V, Bodet-Milin C, Moreau A, Gastinne T, Mahé B, Dubruille V, et al. Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients. Bone Marrow Transplant. 2011;46:393–9.PubMedCrossRef

Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2002;13:1356–63.PubMedCrossRef

Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica. 2006;91:475–81.PubMed

Casasnovas RO, Meignan M, Berriolo-Riedinger A, Bardet S, Julian A, Thieblemont C, et al. SUV_max reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118:37–43.PubMedCrossRef

Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, et al. [18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376–81.PubMedCrossRef

Kasamon YL, Wahl RL, Ziessman HA, Blackford AL, Goodman SN, Fidyk CA, et al. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Transplant. 2009;15:242–8.PubMedCrossRef

10.

Pregno P, Chiappella A, Bellò M, Botto B, Ferrero S, Franceschetti S, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. 2012;119:2066–73.PubMedCrossRef

11.

Zijlstra JM, Boellaard R, Hoekstra OS. Interim positron emission tomography scan in multi-center studies: optimization of visual and quantitative assessments. Leuk Lymphoma. 2009;50:1748–9.PubMedCrossRef

12.

Juweid ME, Stoobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of International Harmonization Project in lymphoma. J Clin Oncol. 2007;25:571–8.PubMedCrossRef

13.

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.PubMedCrossRef

14.

Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51:25–30.PubMedCrossRef

15.

Bodet-Milin C, Touzeau C, Leux C, Sahin M, Moreau A, Maisonneuve H, et al. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging. 2010;37:1633–42.PubMedCrossRef

16.

Meignan M, Barrington S, Itti E, Gallamini A, Haioun C, Polliack A. Report on the 4th international workshop on positron emission tomography in lymphoma held in Menton, France, 3–5 October 2012. Leuk Lymphoma. 2012 (Epub ahead of print).

17.

Moulin-Romsee G, Hindié E, Cuenca X, Brice P, Decaudin D, Bénamor M, et al. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging. 2010;37:1095–105.PubMedCrossRef

18.

Mittal BR, Manohar K, Malhotra P, Das R, Kashyap R, Bhattacharya A, et al. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging? Leuk Lymphoma. 2011;52:2111–6.PubMedCrossRef

19.

Chen YK, Yeh CL, Tsui CC, Liang JA, Chen JH, Kao CH. F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis. Clin Nucl Med. 2011;36:553–9.PubMedCrossRef

20.

Richardson SE, Sudak J, Warbey V, Ramsay A, McNamara CJ. Routine bone marrow biopsy is not necessary in the staging of patients with classical Hodgkin lymphoma in the 18F-fluoro-2-deoxyglucose positron emission tomography era. Leuk Lymphoma. 2012;53:381–5.PubMedCrossRef

21.

El-Galaly TC, d’Amore F, Mylam KJ, de Nully Brown P, Bøgsted M, Bukh A, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naïve patients with Hodgkin lymphoma. J Clin Oncol. 2012;30:4508–14.

22.

Dupuis J, Itti E, Rahmouni A, Hemery F, Gisselbrecht C, Lin C, et al. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol. 2009;20:503–7.PubMedCrossRef

23.

Magagnoli M, Marzo K, Balzarotti M. Dimension of residual CT scan mass in Hodgkin’s lymphoma (HL) is a negative prognostic factor in patients with PET negative after chemo ± radiotherapy. Blood. 2011;118:S93.CrossRef

24.

Dabaja BS, Phan J, Medeiros LJ, Hagemeister FB, Chuang H, Fayad L, et al. Clinical implications of PET-negative residual disease at the completion of chemotherapy for diffuse large B-Cell lymphoma. Blood. 2011;118:S2695.

25.

Song MK, Chung JS, Shin HJ, Lee SM, Lee SE, Lee HS, et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. 2012;91:697–703.PubMedCrossRef

26.

Song MK, Chung JS, Shin HJ, Lee SM, Lee SE, Lee HS, et al. Prognostic value of metabolic tumor volume on PET/CT in primary gastrointestinal diffuse large B cell lymphoma. Cancer Sci. 2012;103:477–82.PubMedCrossRef

27.

Tateishi U, Miyake M, Nagaoka T, Terauchi T, Kubota K, Kinoshita T, et al. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging—prospective assessment. Radiology. 2012;263:53–63.PubMedCrossRef

28.

Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, et al. Positron emission tomography–computed tomography (PET–CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET–CT in a subset of PRIMA trial participants. J Clin Oncol. 2011;29:3194–200.PubMedCrossRef

29.

Dupuis J. B-RA, Julian A, Brice P, Tychyj-Pinel C, Tilly H, Mounier N, et al. Impact of [18F]Fluorodeoxyglucose PET response evaluation in high-tumor burden follicular lymphoma patients treated with immuno-chemotherapy (a prospective study from the GELA & GOELAMS). J Clin Oncol. 2012;30:4317–22.PubMedCrossRef

30.

Mato AR, Svoboda J, Feldman T, Zielonka T, Agress H, Panush D, et al. Post-treatment (not interim) positron emission tomography–computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. Cancer. 2012;118:3565–70.PubMedCrossRef

31.

Cahu X, Bodet-Milin C, Brissot E, Maisonneuve H, Houot R, Morineau N, et al. 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. Ann Oncol. 2011;22:705–11.PubMedCrossRef

32.

Feeney J, Horwitz S, Gönen M, Schöder H. Characterization of T-cell lymphomas by FDG PET/CT. AJR Am J Roentgenol. 2010;195:333–40.PubMedCrossRef

33.

Khandani AH, Dunphy CH, Meteesatien P, Dufault DL, Ivanovic M, Shea TC. Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography. Nucl Med Commun. 2009;30:594–601.PubMedCrossRef

34.

Hartmann S, Agostinelli C, Diener J, Döring C, Fanti S, Zinzani PL, et al. GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers. BMC Cancer. 2012;2:586.CrossRef

35.

Watanabe Y, Suefuji H, Hirose Y, Kaida H, Suzuki G, Uozumi J, et al. 18F-FDG uptake in primary gastric malignant lymphoma correlates with glucose transporter 1 expression and histologic malignant potential. Int J Hematol. 2013;97:43–9.PubMedCrossRef

36.

Cox MC, Ambrogi V, Lanni V, Cavalieri E, Pelliccia S, Scopinaro F, et al. Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy. Leuk Lymphoma. 2012;53:263–9.PubMedCrossRef

37.

Kawano T, Suzuki A, Ishida A, Takahashi N, Lee J, Tayama Y, et al. The clinical relevance of thymic fluorodeoxyglucose uptake in pediatric patients after chemotherapy. Eur J Nucl Med Mol Imaging. 2004;31:831–6.PubMedCrossRef

38.

Shammas A, Lim R, Charron M. Pediatric FDG PET/CT: physiologic uptake, normal variants, and benign conditions. Radiographics. 2009;29:1467–86.PubMedCrossRef

39.

Kamel EM, Goerres GW, Burger C, von Schulthess GK, Stenert HC. Recurrent laryngeal nerve palsy in patients with lung cancer: detection with PET–CT image fusion: report of six cases. Radiology. 2002;224:153–6.PubMedCrossRef

40.

Lerman H, Mtese U, Grisaru D, Fishman A, Lievshitz G, Even-Sapir E. Normal and abnormal ¹⁸F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med. 2004;45:266–71.PubMed

41.

Yeung HWD, Grewal RK, Gonen M, Schoder H, Larson SM. Patterns of ¹⁸F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med. 2003;44:1789–96.PubMed

42.

Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol. 2004;22:4442–5.PubMedCrossRef

43.

Meignan M, Gallamini A, Itti E, Barrington S, Haioun C, Polliack A. Report on the Third International Workshop on Interim positron emission tomography in lymphoma held in Menton, France, 26–27 September 2011 and Menton 2011 consensus. Leuk Lymphoma. 2012;53:1876–81.PubMedCrossRef

44.

Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL. (18)F-FDG PET/CT for early response assessment in diffuse large b-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med. 2011;52:386–92.PubMedCrossRef

45.

Mikhaeel NG, Hutchings M, Fields PA, O’Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16:1514–23.PubMedCrossRef

46.

Itti E, Lin C, Dupuis J, Paone G, Capacchione D, Rahmouni A, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50:527–33.PubMedCrossRef

47.

Itti E, Meignan M, Berriolo-Riedinger A, Biggi A, Cashen AF, Véra P, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUV_max. Eur J Nucl Med Mol Imaging. 2013 (Epub ahead of print).

48.

Daisaki H, Tateishi U, Terauchi T, Tatsumi M, Suzuki K, Shimada N, et al. Standardization of image quality across multiple centers by optimization of acquisition and reconstruction parameters with interim FDG-PET/CT for evaluating diffuse large B cell lymphoma. Ann Nucl Med. 2012 (Epub ahead of print).

49.

Tateishi U, Nakamoto Y, Murakami K, et al. Guidelines for PET examination using in-house-produced FDG (2nd edition) (Japanese Society of Nuclear Medicine). Jpn J Nucl Med (Kaku Igaku). 2005;42:1–22. http://www.jsnm.org/files/pdf/guideline/fdg_guide2-2.pdf.

50.

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S–50S.PubMedCrossRef

51.

Fukukita H, Senda M, Terauchi T, Suzuki K, Daisaki H, Matsumoto K, et al. Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of Version 1.0. Ann Nucl Med. 2010;24:325–34.PubMedCrossRef

52.

Buchbender C, Heusner TA, Lauenstein C, Bockisch A, Antoch G. Oncologic PET/MRI, part 1: tumor of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med. 2012;53:928–38.PubMedCrossRef

53.

Buchbender C, Heusner TA, Lauenstein C, Bockisch A, Antoch G. Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med. 2012;53:1244–52.PubMedCrossRef

54.

Platzek I, Beuthien-Baumann B, Schneider M, Gudziol V, Langner J, Schramm G, et al. PET/MRI in head and neck cancer: initial experience. Eur J Nucl Med Mol Imaging. 2013;40:6–11.PubMedCrossRef

55.

Kaneta T. A brief review of Japanese guidelines for the clinical use of ¹⁸F-FDG-PET/MRI 2012 (Ver 1.0). Ann Nucl Med. 2013 (Epub ahead of print).

56.

Buck AK, Kratochwill C, Glatting G, Juweid ME, Bommer M, Tepsic D, et al. Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. Eur J Nucl Med Mol Imaging. 2007;34:1775–82.PubMedCrossRef

57.

Buck AK, Bommer M, Stlingenbauer S, Juweid M, Glatting G, Schirrmeister H, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res. 2006;66:11055–61.PubMedCrossRef

Title: PET/CT in malignant lymphoma: basic information, clinical application, and proposal
Author: Ukihide Tateishi
Publication date: 01-10-2013
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 4/2013
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-013-1444-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

Ex vivo activation of angiogenic property in human peripheral blood-derived monocytes by thrombopoietin

Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial

Refractoriness to platelet transfusion in acute myeloid leukemia correlated with the optical density of anti-platelet factor 4/heparin antibodies

Myeloid/NK cell acute leukemia with unique blast morphology: de novo or secondary leukemia?

Erdheim–Chester disease and Schnitzler syndrome: so near, and yet so far

Evaluating the efficacy and safety of apixaban, a new oral anticoagulant, using Bayesian meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer